Latent TGF-beta bp4 Protein, Human (HEK293, His)
Based on 1 Customer Validation
Latent TGF-β binding protein 4 (LTBP4) plays a critical role in the TGFB1, TGFB2, and TGFB3 signaling pathways, maintaining TGF-β in a latent state during extracellular storage. LTBP4 complexly regulates integrin-dependent TGF-β activation through specific disulfide interactions with latency-associated peptide (LAP). Latent TGF-beta bp4 Protein, Human (HEK293, His) is the recombinant human-derived Latent TGF-beta bp4 protein, expressed by HEK293 , with C-6*His labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- Help & FAQs
Biological Activity
Description
Latent TGF-β binding protein 4 (LTBP4) plays a critical role in the TGFB1, TGFB2, and TGFB3 signaling pathways, maintaining TGF-β in a latent state during extracellular storage. LTBP4 complexly regulates integrin-dependent TGF-β activation through specific disulfide interactions with latency-associated peptide (LAP). Latent TGF-beta bp4 Protein, Human (HEK293, His) is the recombinant human-derived Latent TGF-beta bp4 protein, expressed by HEK293 , with C-6*His labeled tag.
Background
Latent TGF-beta binding protein 4 (LTBP4) serves as a pivotal regulator in the transforming growth factor beta (TGFB1, TGFB2, and TGFB3) signaling pathway by maintaining TGF-beta in a latent state during extracellular storage. Through specific disulfide bond interactions with the Latency-associated peptide (LAP), the regulatory chain of TGF-beta, LTBP4 intricately modulates integrin-dependent TGF-beta activation. As an integral component of the large latent transforming growth factor beta precursor complex, LTBP4's removal is deemed essential for the subsequent activation of the complex. Notably, LTBP4 engages in interactions with LTBP1 and TGFB1, contributing to the orchestration of TGF-beta signaling dynamics. Additionally, LTBP4 interacts with EFEMP2, promoting the fibrillar deposition of EFEMP2 and further influencing the regulatory network of TGF-beta activation.
Verified Bioactivity
Immobilized Human Latent TGF-beta bp4 at 2 μg/mL (100 μL/well) can bind Biotinylated Human TGFB1 (HY-P73426). The ED50 for this effect is 1.930 μg/mL.
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
-
Bioactivity - ELISA
Bioactivity - ELISA
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-6*His
-
Accession
Q8N2S1-1 (M1-A1624)
-
Molecular Construction
-
N-term
-
LTBP4 (M1-A1624)
Accession # Q8N2S1-1 -
6*His
-
C-term
-
-
Protein Length
Full Length
-
Synonyms
LTBP4; LTBP-4L; Latent Transforming Growth Factor Beta Binding Protein 4; Latent Transforming Growth Factor-Beta Binding Protein 4L; LTBP-4; ARCL1C; Latent-Transforming Growth Factor Beta-Binding Protein 4; LTBP4L; FLJ46318; LTBP4S; FLJ90018
-
AA Sequence
MPRPGTSGRRPLLLVLLLPLFAAATSAASPSPSPSQVVEVPGVPSRPASVAVCRCCPGQTSRRSRCIRAFCRVRSCQPKKCAGPQRCLNPVPAVPSPSPSVRKRQVSLNWQPLTLQEARALLKRRRPRGPGGRGLLRRRPPQRAPAGKAPVLCPLICHNGGVCVKPDRCLCPPDFAGKFCQLHSSGARPPAPAVPGLTRSVYTMPLANHRDDEHGVASMVSVHVEHPQEASVVVHQVERVSGPWEEADAEAVARAEAAARAEAAAPYTVLAQSAPREDGYSDASGFGYCFRELRGGECASPLPGLRTQEVCCRGAGLAWGVHDCQLCSERLGNSERVSAPDGPCPTGFERVNGSCEDVDECATGGRCQHGECANTRGGYTCVCPDGFLLDSSRSSCISQHVISEAKGPCFRVLRDGGCSLPILRNITKQICCCSRVGKAWGRGCQLCPPFGSEGFREICPAGPGYHYSASDLRYNTRPLGQEPPRVSLSQPRTLPATSRPSAGFLPTHRLEPRPEPRPDPRPGPELPLPSIPAWTGPEIPESGPSSGMCQRNPQVCGPGRCISRPSGYTCACDSGFRLSPQGTRCIDVDECRRVPPPCAPGRCENSPGSFRCVCGPGFRAGPRAAECLDVDECHRVPPPCDLGRCENTPGSFLCVCPAGYQAAPHGASCQDVDECTQSPGLCGRGACKNLPGSFRCVCPAGFRGSACEEDVDECAQEPPPCGPGRCDNTAGSFHCACPAGFRSRGPGAPCQDVDECARSPPPCTYGRCENTEGSFQCVCPMGFQPNTAGSECEDVDECENHLACPGQECVNSPGSFQCRTCPSGHHLHRGRCTDVDECSSGAPPCGPHGHCTNTEGSFRCSCAPGYRAPSGRPGPCADVNECLEGDFCFPHGECLNTDGSFACTCAPGYRPGPRGASCLDVDECSEEDLCQSGICTNTDGSFECICPPGHRAGPDLASCLDVDECRERGPALCGSQRCENSPGSYRCVRDCDPGYHAGPEGTCDDVDECQEYGPEICGAQRCENTPGSYRCTPACDPGYQPTPGGGCQDVDECRNRSFCGAHAVCQNLPGSFQCLCDQGYEGARDGRHCVDVNECETLQGVCGAALCENVEGSFLCVCPNSPEEFDPMTGRCVPPRTSAGTFPGSQPQAPASPVLPARPPPPPLPRRPSTPRQGPVGSGRRECYFDTAAPDACDNILARNVTWQECCCTVGEGWGSGCRIQQCPGTETAEYQSLCPHGRGYLAPSGDLSLRRDVDECQLFRDQVCKSGVCVNTAPGYSCYCSNGYYYHTQRLECIDNDECADEEPACEGGRCVNTVGSYHCTCEPPLVLDGSQRRCVSNESQSLDDNLGVCWQEVGADLVCSHPRLDRQATYTECCCLYGEAWGMDCALCPAQDSDDFEALCNVLRPPAYSPPRPGGFGLPYEYGPDLGPPYQGLPYGPELYPPPALPYDPYPPPPGPFARREAPYGAPRFDMPDFEDDGGPYGESEAPAPPGPGTRWPYRSRDTRRSFPEPEEPPEGGSYAGSLAEPYEELEAEECGILDGCTNGRCVRVPEGFTCRCFDGYRLDMTRMACVDINECDEAEAASPLCVNARCLNTDGSFRCICRPGFAPTHQPHHCAPARPRA
-
Predicted Molecular Mass
174.3 kDa
-
Molecular Weight
Approximately 150-220 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (245 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
